The effect of complex treatment on the course of wound healing in patients with odontogenic phlegmons of the maxillofacial region on the background of liver pathology

Annotation. Odontogenic inflammatory processes in the maxillofacial surgery clinic remain one of the current problems. They account for 20-30% of the total number of hospitalized maxillofacial patients. The number of patients is increasing along with the increase in the level of complications and fatalities, especially in patients with liver pathology. The aim of the study is a clinical study of the healing of postoperative purulent wounds in patients with odontogenic phlegmons of the maxillofacial region and concomitant chronic liver diseases and using of hepatoprotectors. Clinical observations were conducted on the results of treatment of 72 patients with odontogenic phlegmons of the cellular spaces of the lower jaw. All patients were divided into three groups: The main group (23 patients) – without concomitant liver pathology. Comparison group №1 (28 patients) – with the chronic liver diseases, who received standard treatment. Comparison group №2 (21 patients) – with chronic liver diseases, who were given 20% 10.0 ml intravenously 2 times a day, and also used Inflarax ointment locally. The results of the study of postoperative wound healing in patients with odontogenic phlegmon showed that in the main group (without liver pathology), the postoperative period had significantly better dynamics compared to comparison group №1 and slightly better dynamics than in patients in comparison group №2. All local inflammation indicators confirmed the negative impact of chronic liver diseases on the wound healing process in patients with odontogenic phlegmon of the maxillofacial region, as well as the positive impact of the hepatoprotector Glutargin in combination with local treatment with Inflarax on the course of the postoperative period. Liver pathology negatively affects the course of odontogenic phlegmon of the maxillofacial region, but the appointment of hepatoprotectors in the complex treatment improves it (p<0.05), while the frequency of complications in odontogenic phlegmon in patients with concomitant liver pathology increases from 9% to 22%, but is leveled when using glutargin and inflarax, reducing the number of complications. Therefore, it is advisable to include glutargin and inflarax in the complex treatment of odontogenic phlegmon in patients with liver pathology.